UNSPSC 51183102: Alrestatin sodium

This classification denotes an aldose reductase inhibitor with the molecular structure C14H8NO4.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 018XNU6812 chemically known as 1h-benz(de)isoquinoline-2(3h)acetic acid, 1,3-dioxo-, sodium salt, but more commonly known as alrestatin sodium, which bears US NIH Compound Identifier 40158. European Medicines Agency schedules Alrestatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00380MIG.

Most nations, for tariff and trade purposes, schedule alrestatin sodium under HS 29251995 and SITC 51482. As of Q4 2014, ALRESTATIN SODIUM remains US FDA's Preferred Term for this commodity. Alrestatin sodium bears US NLM identifiers UMLS ID C2346724 and NCI Concept Code C72691. SMILES: C1CC2CCCC3C2C(C1)C(=O)N(C3=O)CC(=O)[O-].[NA+].

The source provides no recent state and local procurement opportunities under UNSPSC 51183102 Alrestatin sodium, a Commodity code.

Without posted solicitations or awarded contracts in the recent-opportunities block, the scope of work, issuing-body mix, geographic spread, and representative opportunities cannot be characterized from current market signals.